Written by Dr. Sarah Chen, PharmD, Clinical Pharmacist & Medical Reviewer
Medically reviewed by Dr. Michael Torres, MD, Board-Certified Obesity Medicine Physician
Published:
All 5 FDA-Approved Weight Loss Drugs Compared: Wegovy vs Zepbound vs Saxenda vs Contrave vs Qsymia
Complete comparison of all FDA-approved weight loss drugs: Wegovy, Zepbound, Saxenda, Contrave & Qsymia. Efficacy, costs, side effects analyzed by physicians.
Reviewed by FormBlends Medical Team|
In This Article
Quick Winners Summary
- Best Overall: Zepbound (tirzepatide) - Highest efficacy with 22.5% weight loss
- Best Value: Contrave - Lowest cost at $99/month
- Best for Beginners: Saxenda - Proven track record, daily dosing for control
- Best for Complex Cases: Qsymia - Dual-action mechanism for treatment-resistant patients
- Best Accessibility: Wegovy - Widest insurance coverage and pharmacy availability
Master Comparison: All 5 FDA-Approved Weight Loss Drugs
| Factor | Wegovy | Zepbound | Saxenda | Contrave | Qsymia |
|---|---|---|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide | Liraglutide | Naltrexone-Bupropion | Phentermine-Topiramate |
| Average Weight Loss | 14.9% | 22.5% | 8.0% | 8.1% | 10.9% |
| Monthly Cost | $1,349 | $1,060 | $1,349 | $99 | $230 |
| Administration | Weekly injection | Weekly injection | Daily injection | Twice daily oral | Once daily oral |
| Insurance Coverage | 65% | 45% | 55% | 40% | 50% |
| Common Side Effects | Nausea, vomiting, diarrhea | Nausea, vomiting, diarrhea | Nausea, hypoglycemia | Nausea, constipation, headache | Dry mouth, tingling, insomnia |
| FDA Approval Date | June 2021 | November 2023 | December 2014 | September 2014 | July 2012 |
Wegovy (Semaglutide): The Market Leader
Wegovy represents the current gold standard in prescription weight loss medications, with the most strong clinical data and widest real-world adoption. This GLP-1 receptor agonist mimics the hormone that regulates blood sugar and slows gastric emptying, creating sustained satiety and reduced food cravings. Key Strengths:- Proven efficacy: The STEP clinical trials demonstrated 14.9% average weight loss over 68 weeks, with 83.5% of participants losing at least 5% of their body weight
- Insurance coverage: Approximately 65% of commercial insurance plans now cover Wegovy, the highest rate among all weight loss medications
- Convenient dosing: Once-weekly injection reduces the burden of daily medication management
- High cost: At $1,349 per month without insurance, Wegovy remains financially inaccessible for many patients
- Supply issues: Manufacturing constraints have led to periodic shortages since launch
- Gastrointestinal effects: Up to 44% of patients experience nausea, particularly during dose escalation phases
Zepbound (Tirzepatide): The Newest Powerhouse
Zepbound, approved in November 2023, represents the most potent weight loss medication currently available. This dual GIP/GLP-1 receptor agonist targets two hormone pathways simultaneously, resulting in superior weight loss compared to single-mechanism drugs. Key Strengths:- Highest efficacy: SURMOUNT-1 trial data shows 22.5% average weight loss at the highest dose, exceeding all other FDA-approved options
- Dual mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effects
- Lower cost than Wegovy: List price of $1,060 per month makes it more accessible than semaglutide options
- Limited insurance coverage: As the newest option, only 45% of plans currently cover Zepbound
- Similar side effects: Gastrointestinal effects mirror those of other GLP-1 medications
- Limited real-world data: Short time on market means fewer patient experience reports
Saxenda (Liraglutide): The Established Option
Saxenda holds the distinction of being the first GLP-1 receptor agonist approved specifically for weight management. With nearly a decade of clinical use, it offers the most extensive real-world safety and efficacy data among the injection-based options. Key Strengths:- Longest track record: Approved since 2014 with extensive post-market surveillance data
- Daily dosing flexibility: Patients can adjust timing and develop consistent routines
- Moderate insurance coverage: About 55% of plans provide coverage, better than newer options
- Lower efficacy: 8.0% average weight loss lags behind newer GLP-1 options
- Daily injections: More frequent dosing increases treatment burden
- Higher hypoglycemia risk: Daily dosing can lead to more blood sugar fluctuations
Contrave (Naltrexone-Bupropion): The Oral Alternative
Contrave offers the only oral medication option that specifically targets both appetite and reward pathways in the brain. This combination of an opioid receptor antagonist and an antidepressant provides a unique mechanism distinct from the injection-based GLP-1 medications. Key Strengths:- Lowest cost: At $99 per month, Contrave is the most affordable FDA-approved weight loss medication
- Oral administration: No injections required, improving patient acceptance and compliance
- Dual brain targets: Addresses both hunger and food reward pathways simultaneously
- Moderate efficacy: 8.1% average weight loss is lower than injection options
- Multiple contraindications: Cannot be used with seizure disorders, eating disorders, or MAO inhibitors
- Twice-daily dosing: Requires consistent medication adherence throughout the day
Qsymia (Phentermine-Topiramate): The Veteran Performer
Qsymia combines the oldest FDA-approved weight loss ingredient (phentermine) with an anti-seizure medication (topiramate) that has weight loss properties. This dual-action approach provides appetite suppression and metabolic enhancement through complementary mechanisms. Key Strengths:- Proven long-term data: Over 12 years of post-market experience with consistent safety profile
- Moderate cost: $230 per month makes it more accessible than injection options
- Once-daily dosing: Simple dosing schedule improves medication adherence
- Controlled substance: Phentermine component requires DEA registration and monitoring
- Cognitive effects: Topiramate can cause concentration difficulties and word-finding problems
- Birth defect risk: Requires pregnancy prevention measures in women of reproductive age
Price Showdown: Who's Cheapest?
Cost represents the primary barrier to accessing prescription weight loss medications, with dramatic price differences across the five FDA-approved options. Our analysis of current list prices reveals a 13-fold difference between the most and least expensive treatments. Winner: Contrave at $99/month Contrave dominates the affordability category at $99 per month for the standard dose. This oral combination medication costs less than most patients spend on monthly gym memberships or meal delivery services. The low cost stems from both active ingredients being available as generics, though the specific combination formulation remains under patent protection. Qsymia ranks second at $230 per month, representing reasonable value given its dual-mechanism approach and once-daily convenience. The controlled substance status adds administrative costs but doesn't significantly impact the patient price. Zepbound, despite being the newest option, offers competitive pricing at $1,060 monthly. Eli Lilly's strategic pricing positions it below Wegovy while delivering superior efficacy, creating strong value proposition for patients who can access it. Both Wegovy and Saxenda command premium pricing at $1,349 per month. Novo Nordisk's pricing reflects their market leadership position, though the cost creates significant access barriers for uninsured patients. Insurance coverage patterns significantly impact real-world costs. Wegovy enjoys the broadest coverage at 65% of commercial plans, while newer options like Zepbound face more limited coverage. Patients should verify their specific plan benefits before making treatment decisions, as copays can range from $25 to over $300 monthly even with coverage.Medication Selection: Who Offers What?
The five FDA-approved weight loss medications represent four distinct drug classes and three different administration methods, providing options for diverse patient needs and preferences. Winner: Tie between Zepbound and Wegovy for mechanism innovation Zepbound leads in pure efficacy through its dual GIP/GLP-1 receptor targeting, representing the most advanced mechanism currently available. The dual pathway approach addresses multiple aspects of weight regulation simultaneously, explaining its superior clinical outcomes. Wegovy offers the most refined GLP-1 experience, with extensive dose optimization studies and the longest clinical follow-up data among weekly injection options. The once-weekly dosing strikes an optimal balance between convenience and sustained drug levels. Saxenda provides the most flexible dosing option with daily injections allowing precise titration and timing adjustments. Patients who prefer more control over their medication schedule often favor this approach. Contrave uniquely targets brain reward pathways through its naltrexone-bupropion combination, addressing the psychological aspects of overeating that other medications don't directly impact. This makes it particularly valuable for emotional eaters. Qsymia combines appetite suppression with metabolic enhancement through its phentermine-topiramate formulation. The stimulant component provides energy boost alongside weight loss, which some patients find beneficial for exercise motivation. Each medication targets different aspects of weight regulation: hormonal (GLP-1 drugs), neurological (Contrave), or metabolic (Qsymia). This diversity allows physicians to match treatments to specific patient presentations and underlying causes of weight gain.Doctor Quality: Who Has Real Oversight?
Physician oversight quality varies significantly across different prescribing platforms and healthcare delivery models. All five medications require prescription and monitoring, but the depth and consistency of medical supervision differs substantially. Winner: Traditional healthcare systems with specialized obesity medicine programs Traditional healthcare systems typically provide the most comprehensive physician oversight, with access to full medical records, laboratory monitoring, and coordinated care teams. Obesity medicine specialists within these systems offer the highest level of expertise in weight management medication selection and monitoring. Telehealth platforms vary widely in their physician oversight quality. Premium services like FormBlends provide physician-supervised care with licensed physicians reviewing each patient case, conducting comprehensive assessments, and providing ongoing monitoring throughout treatment. Direct-to-consumer platforms often provide minimal physician interaction, with some relying on brief questionnaires and automated approvals. These services may miss important contraindications or drug interactions that require clinical judgment to identify. The complexity of these medications demands thorough medical evaluation. Wegovy and Zepbound require assessment for thyroid cancer history and pancreatitis risk. Contrave needs cardiovascular evaluation and seizure history review. Qsymia requires pregnancy prevention counseling and cognitive assessment. Ongoing monitoring needs include regular weight tracking, side effect assessment, and laboratory monitoring for some patients. Quality physician oversight ensures appropriate dose adjustments, manages side effects effectively, and recognizes when medication changes are needed. Patients should seek providers who conduct comprehensive medical histories, explain risks and benefits thoroughly, provide clear instructions for side effect management, and offer accessible communication for questions or concerns during treatment.Speed: Who Ships Fastest?
Medication accessibility and delivery speed have become critical factors in treatment success, particularly for patients eager to begin their weight loss process or those switching from ineffective treatments. Winner: Compounding pharmacies and specialized telehealth services Compounding pharmacies often provide the fastest access to weight loss medications, particularly for semaglutide and tirzepatide formulations. These pharmacies can typically ship within 24-48 hours of prescription approval, compared to 7-14 days for traditional retail pharmacies. Specialized telehealth platforms focusing on weight loss medications maintain simplified supply chains and can often provide same-day or next-day shipping. Their focused inventory management and direct pharmacy relationships enable rapid fulfillment. Traditional retail pharmacies face the longest delays, particularly for newer medications like Zepbound or during supply shortages affecting Wegovy. Insurance prior authorization processes can add 3-7 additional days to delivery times. Manufacturer supply constraints significantly impact availability. Wegovy has experienced multiple shortage periods since launch, sometimes extending wait times to several weeks. Zepbound's newer status means less predictable supply patterns. Patients requiring immediate treatment start should consider multiple fulfillment options simultaneously. Having backup pharmacies identified can prevent treatment delays when primary sources face shortages or insurance complications. Geographic location affects delivery speed, with rural areas typically experiencing longer shipping times. Express shipping options are available through most providers but may add $20-50 to monthly costs.Which One Should You Choose? Our Recommendations
Selecting the optimal weight loss medication requires careful consideration of individual factors including medical history, lifestyle preferences, financial situation, and treatment goals. Our clinical experience suggests specific medications excel in particular scenarios.Best if you're on a tight budget
Recommendation: Contrave At $99 monthly, Contrave provides FDA-approved weight loss treatment at a fraction of injection medication costs. While the 8.1% average weight loss trails injectable options, the affordability makes long-term treatment sustainable for budget-conscious patients. The oral administration eliminates injection-related costs and complexity. Patients save on needles, alcohol swabs, and sharps disposal containers required for injectable medications. Insurance coverage for Contrave varies, but the low cash price makes it accessible even without coverage. Many patients find the out-of-pocket cost comparable to their previous spending on ineffective over-the-counter weight loss supplements. The twice-daily dosing requires commitment but allows for flexible timing around meals and daily routines. Starting with a single daily dose and gradually increasing helps minimize side effects while keeping costs low during the adjustment period.Best if you want premium physician oversight
Recommendation: Wegovy through specialized obesity medicine practices Wegovy's extensive clinical data and established safety profile make it the preferred choice for patients seeking comprehensive medical supervision. The medication's complexity requires experienced physician oversight for optimal outcomes. Specialized obesity medicine physicians bring expertise in managing GLP-1 medications, including dose optimization, side effect mitigation, and combination therapy strategies. Their experience with hundreds of patients provides valuable insights for individualized treatment approaches. The once-weekly dosing simplifies monitoring schedules while providing consistent therapeutic levels. Physicians can more easily track progress and adjust treatment plans with predictable dosing intervals. FormBlends offers physician-supervised Wegovy treatment with comprehensive monitoring and support throughout the weight loss process. Our physicians conduct thorough evaluations and provide ongoing guidance to maximize treatment success while minimizing risks.Best if you need it fast
Recommendation: Compounded semaglutide or tirzepatide Compounded versions of semaglutide and tirzepatide offer the fastest access to GLP-1 medications, often shipping within 24-48 hours of prescription approval. These formulations provide equivalent active ingredients to brand-name versions at reduced costs. Compounding pharmacies maintain ready inventory and simplified fulfillment processes specifically designed for rapid delivery. Their specialized focus on weight loss medications eliminates common delays associated with traditional pharmacy operations. Patients switching from other medications can transition quickly without treatment gaps that might trigger weight regain. The rapid access prevents motivation loss that often occurs during extended waiting periods. Quality compounding pharmacies follow strict FDA guidelines and provide certificates of analysis confirming medication potency and purity. Patients should verify their chosen pharmacy meets all regulatory requirements for compounded medications.Best for long-term comprehensive support
Recommendation: Zepbound with structured program support Zepbound's superior efficacy makes it ideal for patients committed to comprehensive, long-term weight management programs. The 22.5% average weight loss provides substantial results that justify intensive support investments. Comprehensive programs combining Zepbound with nutritional counseling, behavioral therapy, and exercise guidance maximize the medication's potential. The higher efficacy creates more dramatic lifestyle changes that require professional support to maintain. The once-weekly dosing fits well with structured program schedules, allowing coordination with counseling sessions and progress monitoring appointments. Patients can align their injection day with weekly check-ins or support group meetings. Long-term success with any weight loss medication requires lifestyle modifications that extend beyond pharmaceutical intervention. Programs that address underlying eating behaviors, stress management, and sustainable nutrition habits provide the foundation for maintaining weight loss after medication discontinuation.What Each Provider Could Improve
Even the most effective weight loss medications have areas for improvement that would enhance patient outcomes and treatment accessibility. Our clinical experience identifies specific limitations that manufacturers and healthcare providers should address. Wegovy improvements needed: Novo Nordisk should prioritize manufacturing capacity expansion to eliminate recurring shortages that disrupt patient treatment. The company could also develop patient assistance programs with more generous income thresholds to improve accessibility. A lower-dose maintenance option might help patients maintain weight loss at reduced cost. Zepbound improvements needed: Eli Lilly needs to accelerate insurance coverage negotiations to match Wegovy's accessibility. The company should publish more real-world effectiveness data as it becomes available and develop clearer guidelines for patients transitioning from other GLP-1 medications. Saxenda improvements needed: The daily injection burden could be reduced through longer-acting formulations or alternative delivery methods. Novo Nordisk should consider developing a weekly version of liraglutide to compete with newer options while maintaining the medication's established safety profile. Contrave improvements needed: The twice-daily dosing creates adherence challenges that a once-daily formulation could address. Additional clinical studies comparing Contrave to newer medications would help position it more effectively in treatment algorithms. Qsymia improvements needed: The cognitive side effects from topiramate limit patient acceptance and could be addressed through dose optimization or alternative combinations. VIVUS should expand research into the medication's cardiovascular benefits to justify its position relative to newer options. FormBlends improvements needed: While our physician oversight and compounded medication access provide excellent value, we could enhance our service by expanding insurance acceptance and developing more comprehensive lifestyle support programs to complement our medical treatments.
Frequently Asked Questions
Can I switch between different weight loss medications?
Yes, patients can switch between weight loss medications under physician supervision. Switching typically requires a washout period of 1-2 weeks to prevent drug interactions and allow accurate assessment of the new medication's effects. Your physician will consider your response to the current medication, side effects experienced, and treatment goals when recommending switches. Some patients benefit from trying multiple options to find their optimal treatment.Do these medications work without diet and exercise?
While FDA-approved weight loss medications can produce weight loss without lifestyle changes, combining them with diet and exercise significantly improves outcomes. Clinical trials showing the impressive weight loss percentages included lifestyle counseling as part of the study protocol. Medications address the physiological aspects of weight loss by reducing appetite and cravings, making it easier to maintain healthy eating habits and exercise routines.How long do I need to take weight loss medications?
Weight loss medications are typically prescribed for long-term use, as obesity is a chronic medical condition. Most patients require ongoing treatment to maintain their weight loss, similar to how diabetes or hypertension medications are used long-term. Clinical studies suggest that discontinuing weight loss medications often leads to weight regain. Your physician will monitor your progress and may adjust dosing or consider medication holidays based on your individual response.Are compounded versions of these medications safe and effective?
Compounded versions of semaglutide and tirzepatide can be safe and effective when prepared by licensed compounding pharmacies following FDA guidelines. These pharmacies must meet strict quality standards and provide certificates of analysis confirming medication potency and purity. However, compounded medications are not FDA-approved and may have different inactive ingredients than brand-name versions. Patients should only use compounded medications from reputable pharmacies with proper oversight.Which medication has the fewest side effects?
Side effect profiles vary between medications and individual patients. Qsymia typically has the lowest rate of gastrointestinal side effects but may cause cognitive effects and sleep disturbances. Contrave avoids the nausea common with GLP-1 medications but can cause headaches and constipation. GLP-1 medications (Wegovy, Zepbound, Saxenda) share similar side effect profiles, with nausea being the most common. Starting with lower doses and gradual titration helps minimize side effects across all medications.Do insurance companies cover weight loss medications?
Insurance coverage for weight loss medications varies significantly by plan and medication. Wegovy has the highest coverage rate at approximately 65% of commercial plans, while newer medications like Zepbound have lower coverage rates. Many plans require prior authorization and documentation of medical necessity, including BMI requirements and previous weight loss attempts. Patients should contact their insurance provider to verify coverage before starting treatment.Can I take weight loss medications if I have diabetes?
Many weight loss medications can be used by patients with diabetes, though dosing adjustments may be necessary. GLP-1 medications (Wegovy, Zepbound, Saxenda) can actually improve blood sugar control and may allow reduction of diabetes medications. Contrave and Qsymia require careful monitoring in diabetic patients due to potential interactions with diabetes medications. Patients with diabetes should work closely with their healthcare providers to coordinate weight loss and diabetes treatments.Ready to Start Your Weight Loss Goals?
Our physician-supervised weight loss programs provide access to all FDA-approved medications with comprehensive medical oversight and ongoing support. Take our free physician assessment to determine which treatment option is right for you.
Explore our patient success stories and learn more about our evidence-based approach to weight management.
Sources & References
- Wilding, J.P.H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989-1002.
- Jastreboff, A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205-216.
- Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11-22.
- Apovian, C.M., et al. (2013). A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity, 21(5), 935-943.
- Gadde, K.M., et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet, 377(9774), 1341-1352.
- FDA Drug Approvals and Databases. (2024). Accessed March 2026. https://www.fda.gov/drugs/drug-approvals-and-databases
- GoodRx Prescription Drug Pricing Database. (2026). Accessed March 2026. https://www.goodrx.com
- IQVIA Institute for Human Data Science. (2025). Medicine Use and Spending in the U.S.: A Review of 2024 and Outlook to 2029.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. The information provided should not be used for diagnosing or treating a health problem or disease. Always consult with a qualified healthcare provider before starting any weight loss medication or making changes to your treatment plan. Individual results may vary, and not all patients will achieve the average weight loss percentages cited in clinical studies. Weight loss medications may cause side effects and have contraindications that require medical evaluation.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The information provided has been reviewed by licensed healthcare professionals but should not replace a consultation with your physician. Individual results vary. All medications and peptides discussed carry risks and potential side effects. Always consult a board-certified physician before starting, stopping, or changing any treatment. FormBlends provides physician-supervised telehealth services; all prescriptions require physician approval based on individual medical evaluation.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are reviewed by licensed physicians but are not a substitute for a personal medical consultation.
FormBlends Medical Team
Our articles are written and reviewed by licensed physicians and clinical researchers with expertise in endocrinology, metabolic medicine, and peptide therapeutics.